1008779-94-9

Usage

Uses

Used in Pharmaceutical Research:
3-Piperidinecarboxylic acid, 3-hydroxy-, Methyl ester is used as a key intermediate in pharmaceutical research for the synthesis of various drug candidates. Its unique structure allows for the creation of new compounds with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 3-Piperidinecarboxylic acid, 3-hydroxy-, Methyl ester serves as a versatile building block for the assembly of complex organic molecules. Its reactivity and functional groups make it a valuable component in the synthesis of a wide range of organic compounds.
Used in Drug Development:
3-Piperidinecarboxylic acid, 3-hydroxy-, Methyl ester is utilized in drug development as a precursor for the creation of new pharmaceuticals. Its potential applications in medicine are being explored due to its distinctive chemical properties, which may contribute to the discovery of novel treatments for various diseases and conditions.
It is crucial to handle 3-Piperidinecarboxylic acid, 3-hydroxy-, Methyl ester with care and adhere to safety protocols when working with it in a laboratory environment to ensure the safety of researchers and the integrity of the experiments.

Upstream product

• 1265323-70-3 tert-butyl 3-cyano-3-(trimethylsilyloxy)piperidine-1-carboxylate 
• 67-56-1 methanol 
• 1219832-34-4 tert-butyl 3-cyano-3-hydroxypiperidine-1-carboxylate 
• 112197-88-3 3-hydroxy-3-(methoxycarbonyl)-1-(phenylmethyl)piperidine 
• 98977-36-7 3-oxo-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 923010-85-9 1'-tert-butyl 3-methyl 3-hydroxy-1,4'-bipiperidine-1',3-dicarboxylate 
• 112197-88-3 3-hydroxy-3-(methoxycarbonyl)-1-(phenylmethyl)piperidine 
• 923010-86-0 C₂₀H₃₃N₃O₅ 
• 923010-55-3 C₁₉H₃₁N₃O₅ 
• 1008779-95-0 1-benzyl-3-methyl-3-hydroxypiperidine-1,3-dicarboxylate 

Relevant academic research and scientific papers

CYCLIC AMIDES AS METAP-2 INHIBITORS

Compounds of the formula (I), in which R1, R3, R5, R6, R7, R, X and Y have the meanings indicated in Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumou

COGNITION ENHANCING COMPOUNDS AND COMPOSITIONS, METHODS OF MAKING, AND METHODS OF TREATING

The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine, receptors and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives compositions, and preparations thereof. Methods of synthesizing oxadiazole compounds also are provided. This disclosure also relates in part to compositions for enhancing cognitive function in subjects such as humans. The compositions comprising a muscarinic agonist or a pharma.ceutically suitable form thereof. This disclosure relates in part to methods of treating animals such as humans by administering such compositions.

Design, synthesis, and structure-activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors

Spiro-lactone (S)-1 is a potent acetyl-CoA carboxylase (ACC) inhibitor and was found to be metabolically liable in human hepatic microsomes. To remove one of the risk factors in human study by improving the metabolic stability, we focused on modifying the

COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING

Disclosed are muscarinic agonist compounds including oxadiazole derivatives, compositions and preparations thereof. Also disclosed are methods of synthesizing such oxadiazole compounds. Further disclosed are methods for treating a subject with said muscarinic agonists or a pharmaceutically suitable form thereof to enhance cognitive function.

SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS

Disclosed are compounds of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is formula (II) Q is a substituted 5-membered monocyclic heteroaryl group; W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

COMPOUNDS AND COMPOSITIONS FOR COGNITION-ENHANCEMENT, METHODS OF MAKING, AND METHODS OF TREATING

Muscarinic agonists, which are useful for stimulating muscarinic receptors and treating cognitive disorders, are provided. Methods of synthesizing such agonists also are provided. Also provided are compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. Also provided are methods of treating animals such as humans by administering such compositions.

BIPHENYL SUBSTITUTED SPIROTETRONIC ACIDS AND THEIR USE FOR THE TREATMENT OF RETROVIRAL DISEASES

The present invention relates to novel substituted spirotetronic acids (I) in which R1 and R2, together with the carbon atom to which they are bonded, form a group of the formula (1), (2), (3) or (4), whereby * represents the carbon

SPIRO-RING COMPOUND

The present invention aims to provide a compound having an acetyl-CoA carboxylase (ACC) inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom or a substituent; ring P is an optionally substituted 6-membered nitrogen-containing aromatic heterocycle; ring Q is an optionally further substituted 5- to 7-membered nitrogen-containing non-aromatic heterocycle; and ring R is an optionally fused 5- to 7-membered non-aromatic ring, which is further optionally substituted, or a salt thereof.